相关实验视频
Updated: May 17, 2025

09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.5K
在病中使用SGLT2抑制剂:我们学到了什么?
Munaza M Akunjee1,2, Shikha G Khosla1,2, Eric S Nylen1,2
1Division of Endocrinology, Department of Medicine, Veterans Affairs Medical Center, Washington, District of Columbia, United States.
American journal of physiology. Endocrinology and metabolism
|April 25, 2025
概括
-葡萄糖共传输体-2 抑制剂 (SGLT2i) 在减缓慢性病 (CKD) 进展方面表现有前途. 这些药物可能为非糖尿病病患者提供显著的心血管和益.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 是一个全球性的健康问题,增加了心血管风险.
- -葡萄糖共传输体-2 抑制剂 (SGLT2i) 在2型糖尿病 (T2DM) 患者中显示出心血管方面的益处.
- 新出现的证据表明,SGLT2i也可能有利于没有糖尿病的患者.
研究的目的:
- 审查SGLT2i在非糖尿病病患者中的疗效.
- 探索SGLT2i脏和心血管保护作用背后的潜在机制.
- 建议考虑SGLT2i对于非糖尿病病的长期益处.
主要方法:
- 使用关键词进行PubMed (2009-2024) 的广泛文献搜索:非糖尿病脏病,糖尿病脏病,SGLT2i,脏结果.
- 对心血管结局试验 (CVOT) 和结局试验的分析.
- 对转化研究的审查,以获得机械学的见解.
主要成果:
- 在没有T2DM的患者中,SGLT2i表现出改善功能和减少白蛋白尿.
- 非糖尿病性病是由特定的eGFR和在没有糖尿病的情况下的白蛋白尿的范围来定义的.
- 通过抗炎和抗纤维机制,SGLT2i与血液动力学和代谢作用一起,通过抗炎和抗纤维机制对脏施加保护.
结论:
- SGLT2i代表了对非糖尿病性脏病的有前途的治疗类.
- 在这个人群中,考虑SGLT2i是有必要的,因为它对心血管和脏有长期益处.
- 对基于细胞的机制的进一步研究可能会阐明SGLT2i的心血管保护作用.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142
Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Antihypertensive Drugs: Direct Renin Inhibitors
458
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
458
Oral Hypoglycemic Agents: Sulfonylureas
167
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
167
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K

